Abbott has entered an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a preclinical monoclonal antibody targeting the cMet receptor for the potential treatment of cancer. The cMet protein is associated with the progression of a range of solid tumors including, prostate, lung and gastric cancers, and mediates resistance to chemotherapy. The companies will also collaborate on research for next-generation cMet antibodies. Under the terms of the ...